Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association

Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve health outcomes and health equity for people with HIV and those who could benefit from pre-exposure prophylaxis. Despite widespread acceptability and demand by providers and potential users of LAIs, implementation has been extremely limited since the introduction of cabotegravir/rilpivirine, the first LAI for HIV treatment, in January 2021, and long-acting cabotegravir, the first LAI for HIV prevention, in December 2021. We report results of a provider survey, conducted by the HIV Medicine Association, which identified LAI implementation barriers related to health insurance processes, staffing and administrative support, drug costs and acquisition, and access for individuals who are uninsured. We provide policy recommendations to address those barriers and facilitate broad and equitable access to LAIs for HIV prevention and treatment, which will be necessary to achieve the goals of the US Ending the HIV Epidemic initiative.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2024-12-20
DOI
https://doi.org/10.1093/cid/ciae648
Citations
13
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
5.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association

Moira McNulty, Tara Vijayan, Samantha E. Dilworth, Elizabeth M Sherman et al.
13 citations
Clinical Infectious Diseases
HIV/AIDS Research and Interventions
5.06
article

Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association

Moira McNulty, Tara Vijayan, Samantha E. Dilworth, Elizabeth M Sherman, Matthew D. Hickey, Jonathan A. Colasanti, Julia L. Marcus, Teaniese L. Davis, Allison L. Agwu, Andrea Weddle, Lauren Frances Collins, José I. Gutierrez, Douglas Krakower, Colleen F. Kelley, Katerina A. Christopoulos, Sheila Montalvo
article en
13 citations

Abstract

Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve health outcomes and health equity for people with HIV and those who could benefit from pre-exposure prophylaxis. Despite widespread acceptability and demand by providers and potential users of LAIs, implementation has been extremely limited since the introduction of cabotegravir/rilpivirine, the first LAI for HIV treatment, in January 2021, and long-acting cabotegravir, the first LAI for HIV prevention, in December 2021. We report results of a provider survey, conducted by the HIV Medicine Association, which identified LAI implementation barriers related to health insurance processes, staffing and administrative support, drug costs and acquisition, and access for individuals who are uninsured. We provide policy recommendations to address those barriers and facilitate broad and equitable access to LAIs for HIV prevention and treatment, which will be necessary to achieve the goals of the US Ending the HIV Epidemic initiative.

Clinical Infectious DiseasesVol. 82(2)
Grady Memorial Hospital (US), Kaiser Permanente (US), Harvard University (US), Johns Hopkins University (US), Emory University (US), University of California, Los Angeles (US), University of California, San Francisco (US), Infectious Diseases Society of America (US), Johns Hopkins Medicine (US), University of California System (US), University of Chicago (US), Grady Health System (US), Memorial Healthcare System (US), Harvard Pilgrim Health Care (US)
National Institute of Mental Health, National Institute of Allergy and Infectious Diseases
Good health and well-being
Openalex Percentile: Top 4%
HIV/AIDS Research and Interventions
5.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.